161 related articles for article (PubMed ID: 37137721)
1. Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug.
Hirosawa K; Fukami T; Nakano M; Nakajima M
Drug Metab Dispos; 2023 Aug; 51(8):1016-1023. PubMed ID: 37137721
[TBL] [Abstract][Full Text] [Related]
2. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans.
Sakai Y; Fukami T; Nagaoka M; Hirosawa K; Ichida H; Sato R; Suzuki K; Nakano M; Nakajima M
Life Sci; 2021 Nov; 284():119896. PubMed ID: 34450168
[TBL] [Abstract][Full Text] [Related]
3. Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans.
Yoshida T; Fukami T; Kurokawa T; Gotoh S; Oda A; Nakajima M
Eur J Pharm Sci; 2018 Jan; 111():167-176. PubMed ID: 28966098
[TBL] [Abstract][Full Text] [Related]
4. Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans.
Honda S; Fukami T; Hirosawa K; Tsujiguchi T; Zhang Y; Nakano M; Uehara S; Uno Y; Yamazaki H; Nakajima M
Drug Metab Dispos; 2021 Sep; 49(9):718-728. PubMed ID: 34135089
[TBL] [Abstract][Full Text] [Related]
5. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases.
Fukami T; Kariya M; Kurokawa T; Iida A; Nakajima M
Eur J Pharm Sci; 2015 Oct; 78():47-53. PubMed ID: 26164127
[TBL] [Abstract][Full Text] [Related]
6. Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog.
Kurokawa T; Fukami T; Yoshida T; Nakajima M
Drug Metab Dispos; 2016 Mar; 44(3):409-16. PubMed ID: 26718653
[TBL] [Abstract][Full Text] [Related]
7. Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.
Xiao D; Shi D; Yang D; Barthel B; Koch TH; Yan B
Biochem Pharmacol; 2013 Feb; 85(3):439-47. PubMed ID: 23228697
[TBL] [Abstract][Full Text] [Related]
8. Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver.
Kobayashi Y; Fukami T; Shimizu M; Nakajima M; Yokoi T
Drug Metab Dispos; 2012 Jun; 40(6):1080-4. PubMed ID: 22446520
[TBL] [Abstract][Full Text] [Related]
9. Indiplon is hydrolyzed by arylacetamide deacetylase in human liver.
Shimizu M; Fukami T; Ito Y; Kurokawa T; Kariya M; Nakajima M; Yokoi T
Drug Metab Dispos; 2014 Apr; 42(4):751-8. PubMed ID: 24464802
[TBL] [Abstract][Full Text] [Related]
10. Hydrolase activities of cynomolgus monkey liver microsomes and recombinant CES1, CES2, and AADAC.
Honda S; Fukami T; Tsujiguchi T; Zhang Y; Nakano M; Nakajima M
Eur J Pharm Sci; 2021 Jun; 161():105807. PubMed ID: 33722734
[TBL] [Abstract][Full Text] [Related]
11. Role of Human Arylacetamide Deacetylase (AADAC) on Hydrolysis of Eslicarbazepine Acetate and Effects of
Hirosawa K; Fukami T; Tashiro K; Sakai Y; Kisui F; Nakano M; Nakajima M
Drug Metab Dispos; 2021 Apr; 49(4):322-329. PubMed ID: 33446525
[TBL] [Abstract][Full Text] [Related]
12. Strain and sex differences in drug hydrolase activities in rodent livers.
Kisui F; Fukami T; Nakano M; Nakajima M
Eur J Pharm Sci; 2020 Jan; 142():105143. PubMed ID: 31726091
[TBL] [Abstract][Full Text] [Related]
13. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase.
Shimizu M; Fukami T; Nakajima M; Yokoi T
Drug Metab Dispos; 2014 Jul; 42(7):1103-9. PubMed ID: 24751575
[TBL] [Abstract][Full Text] [Related]
14. Effects of alcohol on human carboxylesterase drug metabolism.
Parker RB; Hu ZY; Meibohm B; Laizure SC
Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794
[TBL] [Abstract][Full Text] [Related]
15. The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.
Shen Y; Eades W; Liu W; Yan B
Drug Metab Dispos; 2022 Sep; 50(9):1151-1160. PubMed ID: 35790245
[TBL] [Abstract][Full Text] [Related]
16. Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase.
Yasuda K; Watanabe K; Fukami T; Nakashima S; Ikushiro SI; Nakajima M; Sakaki T
Drug Metab Pharmacokinet; 2021 Aug; 39():100397. PubMed ID: 34171773
[TBL] [Abstract][Full Text] [Related]
17. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.
Wang J; Williams ET; Bourgea J; Wong YN; Patten CJ
Drug Metab Dispos; 2011 Aug; 39(8):1329-33. PubMed ID: 21540359
[TBL] [Abstract][Full Text] [Related]
18. Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology.
Nagaoka M; Sakai Y; Nakajima M; Fukami T
Biochem Pharmacol; 2024 May; 223():116128. PubMed ID: 38492781
[TBL] [Abstract][Full Text] [Related]
19. Carboxylesterases and arylacetamide deacetylase comparison in human A549, H460, and H727 pulmonary cells.
Gabriele M; Puccini P; Gervasi PG; Longo V
Life Sci; 2021 Jul; 277():119486. PubMed ID: 33864822
[TBL] [Abstract][Full Text] [Related]
20. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.
Ishizuka T; Yoshigae Y; Murayama N; Izumi T
Drug Metab Dispos; 2013 Nov; 41(11):1888-95. PubMed ID: 23946449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
